Not exact matches
Boehringer Ingelheim stepped away from
flibanserin after the FDA rejected the drug
due to concerns about its efficacy and safety; Goldstein persuaded the Whiteheads to step in.
Due to risks associated with drinking alcohol while taking the drug, the FDA says
flibanserin will only be available through specially certified health care professionals and certified pharmacies.